Excessive pharmacological iron exposure represents a
critical model of iron-induced oxidative stress and iron-mediated cellular
toxicity, where uncontrolled redox reactions promote progressive molecular
damage in circulating erythrocytes. The vulnerability of human red blood cells
to oxidative injury is strongly associated with disruption of hemoglobin
structure, impaired oxygen transport, and deterioration of membrane protein
stability. Evaluation of iron-triggered biochemical alterations provides
important mechanistic insight into the relationship between oxidative stress
biomarkers, hemoglobin oxidation, and erythrocyte dysfunction.
Spectrophotometric assessment from 300 to 650 nm was performed to characterize hemoglobin
conformational changes, alterations in heme oxidation states, and modifications
in oxygen-binding properties. Increased absorbance at 630 nm demonstrated
enhanced methemoglobin formation, indicating oxidation of functional hemoglobin
iron from Fe²⁺ to Fe³⁺ and reduced oxygen-carrying efficiency. Moreover,
elevation of absorbance at 340 nm reflected abnormal heme–globin interaction
and structural rearrangement associated with decreased hemoglobin oxygen
affinity, whereas reduced absorbance at 420 nm confirmed conversion of
oxyhemoglobin into methemoglobin with diminished functional hemoglobin
concentration. A marked increase in hemichrome accumulation further
demonstrated hemoglobin structural instability and oxidative transformation of
the globin–heme complex. In parallel, elevated carbonyl content confirmed
extensive protein oxidation in erythrocytes, establishing protein carbonyls as
sensitive indicators of oxidative protein damage and iron-related redox
imbalance. Analysis of erythrocyte membrane proteins using sodium dodecyl
sulfate polyacrylamide gel electrophoresis revealed the formation of high
molecular weight protein aggregates between 150 and 180 kDa and reduced
α-spectrin band intensity, demonstrating erythrocyte membrane oxidative damage,
cytoskeletal disruption, and impaired cellular integrity. Furthermore, the
positive association between iron concentration and hemoglobin absorbance
changes supports a dose-dependent mechanism of iron overload-induced hemoglobin
dysfunction. Collectively, excessive iron exposure initiates a coordinated
pathway involving reactive oxygen species generation, free radical-mediated
protein modification, hemoglobin conformational remodeling, and red blood cell
functional impairment. These findings highlight the clinical relevance of blood-based
oxidative stress assessment, including methemoglobin measurement, protein
carbonyl evaluation, and hemoglobin spectral analysis, as accessible approaches
for detecting early biochemical consequences of oxidant exposure, iron
toxicity, and erythrocyte injury.
In diabetes mellitus, chronic hyperglycemia drives excessive formation of reactive oxygen species (ROS), establishing a sustained state of oxidative stress biomarker imbalance that contributes to erythrocyte dysfunction and progressive anemia. In advanced renal disease, the hemodialysis environment introduces additional biochemical stressors, amplifying systemic redox disruption and accelerating molecular injury within circulating blood components. Within this context, a clinical cohort consisting of patients with diabetes undergoing hemodialysis, patients with diabetes with preserved renal function, and healthy controls demonstrates distinct biochemical and hematological profiles reflecting graded oxidative injury. Assessment of hemoglobin oxidative modification reveals increased formation of methaemoglobin (Met-Hb), hemichrome accumulation, and measurable hemoglobin conformational changes, indicating structural instability of oxygen-carrying proteins. Concurrent evaluation of plasma demonstrates altered plasma oxidative biomarkers, including significant modulation of ferric reducing ability of plasma (FRAP) as a compensatory antioxidant response, alongside variations in protein carbonyl content (PCO) reflecting protein oxidation burden. Furthermore, biochemical profiling indicates dysregulated metabolic and renal parameters characterized by elevated blood urea nitrogen (BUN), creatinine, and uric acid, together with reduced albumin concentrations, highlighting systemic metabolic impairment. Correlation analyses strengthen mechanistic interpretation, demonstrating strong inverse relationships between protein carbonyl content (PCO) and oxy-hemoglobin stability (r = −0.88), as well as spectral hemoglobin signatures at 340 nm, 420 nm, and 577 nm, suggesting profound erythrocyte oxidative injury and disruption of hemoglobin structural integrity. In parallel, positive correlations between PCO and altered hemoglobin absorbance at 275 nm and 560 nm further confirm oxidative protein remodeling. Collectively, these findings establish a coherent mechanistic axis linking diabetes mellitus oxidative stress, chronic kidney disease oxidative stress, and hemodialysis-associated oxidative stress to progressive hemoglobin dysfunction. Importantly, FRAP antioxidant capacity emerges as a protective redox indicator, whereas protein carbonyl content (PCO) and hemoglobin derivatives function as sensitive negative biomarkers of oxidative injury, reinforcing their value in clinical biochemistry oxidative stress assessment and biomarker-based renal disease monitoring.
Fatemeh Seif, Mohammad Reza Bayatiani, Hadi Ansarihadipour, Ghasem Habibi,Samira Sadelaji
Exposure to extremely low-frequency magnetic fields (ELFMF) has been implicated in the induction of systemic redox imbalance, particularly through disruption of erythrocyte stability and plasma antioxidant defenses; therefore, this experimental study was designed to evaluate the protective properties of Myrtus communis extract against ELFMF-induced oxidative alterations in a controlled in vivo rat model. Adult male rats were allocated into control, ELFMF-exposed, and ELFMF plus Myrtus communis extract administration groups, where a 0.7 mT, 50 Hz magnetic field generated by a Helmholtz coil was applied for one month (2 h/day), while the plant extract was administered intraperitoneally at 0.5 mg/kg prior to exposure. Consequently, biochemical and spectroscopic analyses revealed that ELFMF exposure significantly disrupted hemoglobin conformational integrity, evidenced by increased methemoglobin (metHb) and hemichrome formation, accompanied by a marked reduction in plasma antioxidant capacity measured via ferric reducing ability of plasma (FRAP). In parallel, oxidative injury to plasma proteins was confirmed by elevated protein carbonyl (PCO) levels, indicating extensive protein oxidation under electromagnetic stress conditions. Spectral hemoglobin analysis across 200–700 nm further demonstrated reduced absorbance at 340 nm and 420 nm, reflecting impaired globin–heme interaction and heme–heme stability, respectively, while statistical evaluation using one-way ANOVA confirmed significant intergroup differences at p < 0.001. Importantly, administration of Myrtus communis extract restored antioxidant equilibrium by significantly increasing FRAP values and reducing PCO, metHb, and hemichrome concentrations, thereby indicating strong antioxidant protection in erythrocytes and systemic redox stabilization. Additionally, enhanced absorbance peaks at 340, 420, 542, and 577 nm further confirmed restoration of hemoglobin structural functionality under oxidative challenge. Complementary computational modeling using artificial neural network (ANN) analysis identified optical hemoglobin absorption at 520, 542, 577, and 630 nm, along with metHb and hemichrome levels, as the most predictive determinants of oxyhemoglobin (oxyHb) concentration, demonstrating high sensitivity of machine learning approaches in modeling oxidative hemoglobin dynamics. Collectively, these findings demonstrate that ELFMF-induced oxidative stress can be effectively attenuated by phytochemical intervention, while ANN-based predictive modeling provides a robust framework for interpreting hemoglobin structural transitions under electromagnetic exposure and antioxidant treatment conditions.
Rahmani S, Ansarihadipour H, Bayatiani MR, Khosrowbeygi A, Babaei S, Rasmi Y.
Exposure to Electromagnetic fields (EMF) has been increasingly associated with cellular redox perturbations through the generation of reactive oxygen species, particularly under conditions of extremely low-frequency electromagnetic fields (ELF-EMF), where biological systems exhibit altered susceptibility to oxidative stress. In this investigation, we evaluated β-thalassemia major samples alongside matched controls, focusing on erythrocytes and plasma oxidative status under controlled exposure to 0.5 mT and 1 mT fields at 50 Hz frequency, thereby simulating clinically relevant electromagnetic conditions. Concomitantly, alterations in oxyhemoglobin concentration were quantified using integrated biochemical and computational approaches, while artificial neural networks (ANN) and specifically a multilayer perceptron (MLP) architecture were developed as a feed forward neural network model to predict hemoglobin functionality. Experimental findings demonstrated significant perturbations in optical density of hemoglobin, alongside elevated methemoglobin and hemichrome formation, indicating structural destabilization within the oxygen-carrying system. Furthermore, Native PAGE and SDS-PAGE analyses revealed pronounced protein aggregation, including formation of high molecular weight protein aggregates affecting plasma proteins, consistent with oxidative destabilization patterns. These molecular alterations were corroborated by changes in antioxidant defense system capacity and broader oxidative biomarkers, as assessed through spectrophotometric analysis. Importantly, computational modeling using a regression model demonstrated strong predictive performance with R2=0.942, supported by minimized sum of squares errors (SSR) and reduced relative errors (RE), highlighting robust agreement between observed and predicted outputs. Additionally, exposure-induced hemoglobin structural changes were significantly more pronounced in β-thalassemia patients, suggesting heightened vulnerability compared with healthy donors. Collectively, these findings integrate electromagnetic bioeffects with hematological dysfunction and demonstrate that ELF-EMF exposure modulates redox balance, protein integrity, and hemoglobin stability, while machine learning frameworks such as ANN provide high-accuracy predictive modeling of oxyhemoglobin concentration under both physiological and pathological conditions.
Naghmeh Haddadi, Mehrzad Mirzania, and Hadi Ansarihadipour
Syringic acid (SA) is a phenolic acid compound with antioxidant properties, investigated as a natural antioxidant agent in acute myeloid leukemia (AML), where oxidative stress contributes to disease progression and therapeutic resistance. Our investigation employed a sex- and age-matched design including healthy donors and AML patients at diagnosis, before remission, to evaluate peripheral blood mononuclear cells (PBMCs) and plasma samples under controlled experimental conditions. Samples were divided into a buffer control group (B), an oxidation model (OX), SA pretreatment group (SA+OX), and SA exposure group, allowing assessment of iron-mediated oxidation and reactive oxygen species (ROS) driven alterations in redox homeostasis. Biochemical analyses demonstrated that SA significantly modulated enzyme activity restoration, particularly increasing glutathione peroxidase (GPX), superoxide dismutase (SOD), and catalase (CAT) activities in PBMCs and plasma samples of AML patients. Furthermore, oxidative biomarker modulation was confirmed through reductions in lipid peroxidation and protein carbonylation, indicating improved cellular antioxidant defense and ROS scavenging activity. Additionally, evaluation of total oxidant status (TOS) and total antioxidant status (TAS) revealed that SA effectively restored total antioxidant capacity enhancement in AML biological matrices. Overall, SA exerts oxidative damage protection in a hematological malignancy context by reinforcing antioxidant enzyme networks and restoring redox balance.
Mohamadreza
Bayatiani, Hadi Ansarihadipour, Fatemeh Seif, Samira Sadelaji, Ghasem Habibi
In the era of rapid technological development and increasing environmental exposure, understanding the biological consequences of physical and chemical stressors has become a major focus of biomedical research. Oxidative imbalance represents a central mechanism linking environmental challenges with cellular dysfunction, particularly through excessive reactive oxygen species (ROS) generation, impaired antioxidant networks, and disruption of molecular homeostasis. In this scientific perspective, we explore the emerging concept of environmental stress-induced oxidative injury and its relevance to human and animal health, emphasizing the importance of identifying mechanisms involved in redox regulation, cellular antioxidant defense, and adaptive biological responses. Recent advances in molecular toxicology demonstrate that chronic exposure to environmental factors may influence membrane integrity, protein stability, mitochondrial function, and inflammatory signaling pathways, highlighting the need for integrated approaches in oxidative stress biology and environmental health research. Furthermore, the investigation of naturally derived bioactive compounds has gained considerable attention because of their potential role in strengthening endogenous protection against molecular damage. Plant-based molecules, including polyphenols and flavonoids, are increasingly recognized as promising candidates in natural antioxidant therapy, phytochemical-mediated protection, and regulation of stress-responsive pathways. Through a multidisciplinary framework combining biochemistry, molecular biology, and toxicological assessment, current research is moving toward a deeper understanding of how external stressors interact with biological systems and how targeted interventions can preserve physiological stability. This lecture highlights the importance of advanced biomarkers, translational strategies, and evidence-based antioxidant approaches for addressing challenges associated with oxidative stress-related diseases, molecular damage prevention, and future developments in precision environmental medicine. Ultimately, advancing knowledge of oxidative mechanisms provides a foundation for developing innovative protective strategies aimed at maintaining cellular resilience and improving health outcomes in populations exposed to complex environmental conditions.
Hadi Ansarihadipour, Fatemeh Seif, Mohamad Reza Bayatiani
Exposure to ionizing radiation remains a critical biomedical concern due to its capacity to induce systemic oxidative imbalance by generating excessive reactive oxygen species, thereby disrupting redox homeostasis and impairing macromolecular integrity in circulating blood components. Within this conceptual framework, radiation-induced hemotoxicity is increasingly recognized as a multi-layered process involving structural perturbation of hemoglobin, lipid peroxidation in plasma membranes, and protein oxidation cascades that collectively compromise oxygen transport efficiency and vascular function. In parallel, emerging evidence highlights the role of endogenous and exogenous antioxidant defenses in modulating these deleterious pathways, particularly through modulation of electron transfer reactions and stabilization of heme-protein interactions. In this context, plant-derived phytochemicals have gained attention as potential modulators of oxidative resilience, contributing to redox buffering capacity and restoration of biochemical equilibrium under stress conditions. Experimental observations indicate that radiation exposure disrupts hemoglobin conformational stability, alters spectral absorbance signatures associated with oxyhemoglobin integrity, and elevates oxidative biomarkers such as lipid peroxides and protein carbonyl derivatives, reflecting systemic oxidative burden. Moreover, integrative analytical approaches suggest that machine learning-based predictive modeling can enhance the identification of key biochemical determinants underlying oxygen-carrying capacity, offering a quantitative dimension to oxidative stress assessment. Consequently, the convergence of molecular toxicology, redox biology, and computational analytics provides a comprehensive interpretative platform for understanding radiation-induced hematological injury. Importantly, antioxidant-mediated interventions appear to attenuate oxidative cascades by reinforcing enzymatic defense systems, reducing radical propagation, and preserving structural fidelity of hemoproteins under irradiative conditions. These mechanistic insights collectively underscore the translational relevance of oxidative stress modulation in clinical scenarios such as radiotherapy, where controlled mitigation of collateral oxidative damage may improve therapeutic outcomes. Ultimately, the integration of biochemical markers with predictive modeling frameworks offers a refined strategy for characterizing oxidative susceptibility and advancing precision approaches in radiation biology and blood biochemistry.
Oxidative stress represents a fundamental pathological
mechanism connecting metabolic dysfunction, chronic inflammation, and
progressive cellular injury. Emerging evidence indicates that glucagon-like
peptide-1 (GLP-1) receptor signaling extends beyond its classical incretin
function in glucose regulation and acts as a critical molecular interface
between metabolic control, redox homeostasis, and cellular protection [1–3].
Activation of GLP-1 pathways by endogenous peptide or GLP-1 receptor agonists
regulates intracellular signaling networks involved in oxidative stress
modulation, inflammatory suppression, and tissue preservation [1,4].
At the molecular level, GLP-1 receptor activation stimulates
cAMP-dependent signaling pathways, including protein kinase A (PKA) and exchange
protein directly activated by cAMP (EPAC), which promote adaptive cellular
responses and enhance endogenous antioxidant capacity [2,3]. A major downstream
mechanism involves activation of the Nrf2–Keap1 antioxidant pathway, a master
regulator of cellular redox balance, resulting in increased expression of
antioxidant enzymes, including glutathione peroxidase (GPx) and other
components of the glutathione (GSH) system [5,6]. These coordinated responses
facilitate efficient detoxification of reactive oxygen species (ROS) and
protect cellular macromolecules from oxidative injury [5–7].
Excessive reactive oxygen species accumulation contributes
to mitochondrial dysfunction, lipid peroxidation, protein oxidation, and
oxidative DNA damage, thereby accelerating the progression of type 2 diabetes
mellitus, cardiovascular disorders, and other metabolic diseases [4,7]. GLP-1
signaling counteracts these pathological processes by improving metabolic
efficiency, reducing inflammatory activation, and suppressing key
pro-inflammatory pathways, particularly NF-κB signaling [4,8].
The protective actions of GLP-1 extend across multiple
biological systems, including vascular tissues, metabolic organs, and
circulating blood components [8,9]. In erythrocytes, which lack mitochondria
and nuclei, antioxidant protection depends primarily on enzymatic and
non-enzymatic defense systems, particularly the glutathione-dependent
antioxidant network [6,10]. Therefore, erythrocyte preservation reflects
systemic regulation of oxidative balance rather than direct organelle-mediated
antioxidant activity [10].
Overall, GLP-1 receptor signaling represents a clinically
relevant regulatory axis integrating metabolic signaling, oxidative stress
regulation, inflammatory control, and cellular survival mechanisms [1–4,6].
This molecular framework highlights GLP-1-based therapies as promising
interventions for oxidative stress-related diseases, metabolic disorders, and
conditions characterized by impaired redox regulation.
Metabolic disorders, including type 2 diabetes mellitus,
obesity, and cardiovascular disease, are increasingly recognized as complex
conditions characterized by persistent oxidative imbalance and chronic
low-grade inflammation. Excessive generation of reactive oxygen species (ROS)
combined with impaired antioxidant defense capacity promotes molecular damage,
vascular dysfunction, insulin resistance, and progressive cellular
deterioration [4,7,11].
Although glucagon-like peptide-1 (GLP-1) was initially
identified as an incretin hormone responsible for glucose-dependent insulin
secretion, extensive research has expanded its biological significance beyond
glucose regulation. Current evidence demonstrates that GLP-1 receptor
activation functions as an important regulator of metabolic adaptation,
inflammatory modulation, mitochondrial stability, and cell survival pathways
[1–3]. Pharmacological GLP-1 receptor agonists exhibit therapeutic effects
extending beyond glycemic improvement, including attenuation of oxidative
stress, enhancement of endothelial function, and protection against metabolic
stress-induced cellular injury [1–3,8,12].
The interaction between metabolism and oxidative regulation
represents a complex biological network involving hormonal signals,
intracellular transduction pathways, and endogenous antioxidant systems.
Disruption of redox homeostasis promotes metabolic inflammation, activates
stress-responsive pathways such as NF-κB signaling, and accelerates molecular
damage involving lipid peroxidation, protein oxidation, and oxidative DNA
modification [4–6,13].
Recent studies indicate that GLP-1-dependent mechanisms
restore cellular equilibrium through enhancement of endogenous antioxidant
responses and regulation of key transcriptional defense systems. Among these
pathways, the Nrf2–Keap1 signaling axis represents a central regulator of cellular
antioxidant defense, controlling the expression of cytoprotective enzymes
involved in ROS elimination and maintenance of intracellular redox stability.
Through regulation of the glutathione (GSH) system and antioxidant enzymes,
GLP-1 signaling contributes to preservation of physiological oxidative balance
[5,6,14].
Importantly, experimental and clinical evidence demonstrates
that GLP-1 receptor agonists exert significant anti-inflammatory and
antioxidant effects in vascular and metabolic tissues. These effects include
reduction of endothelial oxidative stress, improvement of nitric oxide
bioavailability, attenuation of inflammatory mediator production, and
protection against chronic metabolic injury [8,9,15].
Understanding the molecular relationship between GLP-1
signaling and oxidative stress regulation provides important insight into
emerging therapeutic approaches targeting metabolic disease, inflammatory
disorders, and redox-associated cellular damage. This integrated perspective
positions GLP-1 as a key molecular regulator connecting metabolism,
inflammation, antioxidant defense, and long-term tissue protection [1–6,12,14].
2. Molecular Mechanisms of GLP-1 Receptor Signaling in
Redox Regulation
The biological effects of glucagon-like peptide-1 (GLP-1)
are initiated through binding to the GLP-1 receptor (GLP-1R), a class B G
protein-coupled receptor (GPCR) expressed in multiple tissues, including
pancreatic β-cells, cardiovascular tissues, immune cells, and metabolic organs
[1–3]. Following receptor activation, intracellular signaling is primarily
mediated through stimulation of adenylate cyclase, resulting in increased
production of cyclic adenosine monophosphate (cAMP) and activation of downstream
signaling pathways involved in metabolic adaptation and cellular stress
resistance [1–3].
The cAMP-dependent signaling cascade, particularly protein
kinase A (PKA) and exchange protein directly activated by cAMP (EPAC) pathways,
represents a central molecular mechanism through which GLP-1 regulates redox
homeostasis, mitochondrial function, inflammation, and antioxidant defense.
These signaling pathways coordinate multiple intracellular responses that
improve cellular adaptation under conditions of metabolic stress and excessive reactive
oxygen species (ROS) generation [2,3,8].
A major consequence of GLP-1 receptor activation is
modulation of the Nrf2–Keap1 antioxidant pathway, which functions as a primary
transcriptional regulator of cellular defense against oxidative injury.
Activation of Nrf2 promotes expression of antioxidant and detoxification genes,
including enzymes associated with the glutathione (GSH) system, glutathione
peroxidase (GPx) activity, and other cytoprotective proteins involved in
maintaining intracellular redox balance [5,6,14]. Through enhancement of these
antioxidant mechanisms, GLP-1 signaling limits excessive ROS accumulation and
reduces oxidative damage to cellular macromolecules [5–7].
In parallel, GLP-1 receptor signaling regulates inflammatory
pathways that contribute to metabolic dysfunction. A key mechanism involves
suppression of excessive NF-κB activation, a major transcriptional pathway
responsible for regulating pro-inflammatory cytokines, adhesion molecules, and
mediators involved in chronic metabolic inflammation. By reducing
NF-κB-dependent inflammatory responses, GLP-1 contributes to restoration of the
balance between inflammatory signaling and antioxidant protection [4,13].
Beyond intracellular antioxidant regulation, GLP-1 signaling
improves vascular redox function by enhancing endothelial nitric oxide (NO)
availability, reducing endothelial oxidative stress, and improving vascular
responsiveness. These mechanisms are particularly important in cardiovascular
tissues, where oxidative injury and inflammation contribute to endothelial
dysfunction, atherosclerosis, and cardiometabolic complications [8,9,15].
Collectively, GLP-1 receptor signaling functions as an
integrated molecular regulator connecting hormonal regulation, oxidative stress
control, inflammatory modulation, and cellular survival pathways. Rather than
acting through a single antioxidant mechanism, GLP-1 coordinates multiple
signaling networks that collectively preserve cellular redox homeostasis and
metabolic stability [1–6,12].
3. GLP-1 and Antioxidant Defense Mechanisms
Oxidative stress develops when the production of reactive
oxygen species (ROS) exceeds the capacity of endogenous antioxidant systems,
resulting in disruption of cellular redox balance and progressive molecular
injury. To maintain physiological function, cells rely on coordinated enzymatic
and non-enzymatic antioxidant defense mechanisms that neutralize reactive
molecules and prevent oxidative propagation reactions [5–8].
Among these protective systems, the glutathione (GSH)
antioxidant pathway represents one of the most important intracellular
mechanisms for maintaining redox stability. Reduced glutathione (GSH) functions
as a major antioxidant reservoir by directly scavenging reactive species and
serving as a substrate for glutathione-dependent enzymes, particularly glutathione
peroxidase (GPx) [6–8]. Maintenance of adequate GSH availability is essential
for protecting proteins, lipids, and nucleic acids against oxidative modification.
The activity of glutathione peroxidase facilitates the
conversion of hydrogen peroxide (H₂O₂) into water, thereby preventing the
formation of highly reactive secondary oxidants. Together with superoxide
dismutase (SOD) and catalase, this enzymatic network forms a coordinated
antioxidant defense system responsible for controlling intracellular ROS levels
and preserving cellular integrity [6–9].
Evidence indicates that GLP-1 signaling enhances endogenous
antioxidant capacity through regulation of intracellular pathways involved in
redox adaptation. Activation of GLP-1 receptors promotes antioxidant responses
through modulation of transcriptional regulators, particularly the Nrf2 pathway,
resulting in increased expression of antioxidant enzymes and improved
resistance against oxidative damage [1–6].
These antioxidant effects are highly relevant in tissues
exposed to chronic metabolic stress, including pancreatic β-cells, vascular
endothelium, liver, and skeletal muscle. In these organs, excessive ROS
production contributes to impaired insulin signaling, mitochondrial
dysfunction, inflammation, and progressive tissue injury. By strengthening
antioxidant defense systems, GLP-1 contributes to improved metabolic resilience,
reduced oxidative burden, and preservation of cellular function [1–6].
Therefore, the relationship between GLP-1 and antioxidant
defense mechanisms represents an important biological link between metabolic
regulation and protection against oxidative injury. Through enhancement of
endogenous antioxidant networks, GLP-1-based therapies provide a potential
strategy for targeting diseases associated with impaired redox regulation and
chronic metabolic inflammation.
4. Oxidative Damage: Lipids, Proteins, and DNA
Oxidative stress represents a major molecular mechanism
underlying cellular dysfunction, in which excessive accumulation of reactive
oxygen species (ROS) exceeds endogenous antioxidant capacity and promotes
progressive damage to essential biological molecules. Disruption of redox
homeostasis affects multiple cellular compartments, resulting in oxidative
modification of lipids, proteins, and nucleic acids and contributing to the
development of chronic metabolic and degenerative disorders [4–7].
4.1 Lipid Peroxidation and Membrane Dysfunction
Cellular membranes are among the primary targets of
oxidative injury because of their high content of polyunsaturated fatty acids.
ROS-mediated abstraction of hydrogen atoms from membrane lipids initiates a
self-propagating lipid peroxidation cascade, resulting in structural and
functional disruption of phospholipid bilayers [4–7].
The progression of lipid peroxidation generates reactive
aldehydes, particularly malondialdehyde (MDA) and 4-hydroxynonenal (4-HNE),
which function as secondary oxidative mediators capable of modifying proteins,
altering signaling pathways, and amplifying cellular injury. Accumulation of
these lipid-derived electrophiles affects membrane fluidity, receptor function,
ion transport, and mitochondrial membrane stability, thereby linking oxidative
damage with metabolic dysfunction and inflammatory activation [4–7].
In metabolic diseases, excessive lipid oxidation contributes
to insulin resistance, endothelial dysfunction, and impaired cellular
communication. Through improvement of antioxidant defense systems and reduction
of ROS production, GLP-1 receptor signaling may attenuate lipid peroxidation
and preserve membrane integrity in metabolically vulnerable tissues [1–6].
4.2 Protein Oxidation and Loss of Cellular Function
Proteins represent another major target of oxidative
molecular damage. Reactive oxygen species can modify amino acid residues,
particularly cysteine, methionine, and tyrosine, leading to protein
carbonylation, abnormal disulfide formation, structural instability, and
impaired biological activity [4–7].
Oxidative modification of enzymes can reduce catalytic
efficiency, disrupt metabolic pathways, and impair cellular signaling networks.
Furthermore, accumulation of oxidized or misfolded proteins may exceed
proteasomal degradation capacity, promoting proteotoxic stress and cellular
dysfunction. These effects are especially significant in tissues with high
metabolic activity, where continuous protein turnover and enzymatic regulation
are essential for maintaining physiological function [4–7].
By reducing excessive ROS generation and enhancing
endogenous antioxidant responses, GLP-1-based therapies may contribute to
preservation of protein stability and improved cellular stress adaptation.
Activation of antioxidant pathways, including the Nrf2–Keap1 signaling pathway,
provides an important mechanism through which GLP-1 limits oxidative protein
injury [5,6,14].
4.3 Oxidative DNA Damage and Genomic Stability
Beyond lipid and protein oxidation, oxidative DNA damage
represents a critical consequence of prolonged ROS exposure. Reactive oxygen
species interact with nucleic acids, producing base modifications, DNA strand
breaks, and chromosomal instability [4–7].
One of the most extensively studied biomarkers of oxidative
DNA injury is 8-hydroxy-2′-deoxyguanosine (8-OHdG), which reflects oxidative
modification of guanine residues and is associated with impaired DNA
replication, mutagenesis, and altered cellular function [4–7]. Although DNA
repair mechanisms can correct many oxidative lesions, persistent oxidative
stress may overwhelm repair capacity, resulting in cellular senescence,
apoptosis, or pathological transformation.
The protective effects of GLP-1 receptor activation against
oxidative injury are mediated primarily through systemic regulation of
metabolism, inflammation, and antioxidant capacity. By improving mitochondrial
efficiency, reducing glucotoxicity and lipotoxicity, and enhancing antioxidant
enzymes such as superoxide dismutase (SOD), catalase, and glutathione
peroxidase (GPx), GLP-1 signaling contributes to preservation of genomic
stability and cellular function [1–6].
Collectively, oxidative modification of lipids, proteins,
and DNA represents an interconnected network of molecular injury that drives
metabolic disease progression. The ability of GLP-1 signaling to regulate
oxidative stress, inflammation, and antioxidant defense mechanisms highlights
its importance as a therapeutic pathway for maintaining cellular protection and
redox balance.
5. GLP-1, Mitochondrial Oxidative Stress, and Metabolic
Adaptation
Mitochondrial dysfunction is a central feature of metabolic
disorders and a major contributor to cellular injury. Mitochondria represent
the primary intracellular source of reactive oxygen species (ROS) under
physiological and pathological conditions, mainly generated as by-products of
oxidative phosphorylation within the electron transport chain [4–8].
Under normal conditions, mitochondrial antioxidant systems
maintain ROS production within physiological limits. However, metabolic
overload, excessive nutrient availability, inflammation, and impaired electron
transport increase electron leakage and promote excessive ROS generation. This
condition, known as mitochondrial oxidative stress, results in reduced ATP
production, impaired bioenergetic efficiency, mitochondrial membrane
instability, and activation of apoptotic signaling pathways [4–8].
These mitochondrial abnormalities are strongly associated
with insulin resistance, cardiovascular disease, obesity-related complications,
and progressive organ dysfunction. Therefore, maintaining mitochondrial quality
control and metabolic adaptation represents a critical component of cellular
protection against oxidative injury [4–8].
GLP-1 receptor signaling has emerged as an important
regulator of mitochondrial homeostasis through activation of intracellular
pathways involving cAMP, PKA, and EPAC signaling. These pathways enhance
mitochondrial efficiency by improving substrate utilization, regulating
oxidative phosphorylation, and reducing pathological electron leakage from
respiratory complexes [2–5].
A key effect of GLP-1 signaling is promotion of mitochondrial
biogenesis, which supports renewal of mitochondrial populations and improves
cellular energetic capacity. Enhanced mitochondrial function contributes to
improved ATP production, stabilization of mitochondrial membrane potential, and
reduction of excessive ROS generation [2–5].
These mechanisms are particularly relevant in metabolically
active tissues, including cardiac muscle, liver, skeletal muscle, and
pancreatic β-cells. In these organs, GLP-1 signaling improves metabolic
flexibility, enhances resistance to cellular stress, and reduces vulnerability
to energy imbalance caused by chronic metabolic overload [1–6].
Importantly, GLP-1 does not directly function as a
mitochondrial antioxidant or interact directly with mitochondrial DNA. Instead,
its protective mitochondrial effects occur mainly through systemic metabolic
regulation. By improving glucose metabolism, reducing lipid accumulation, and
suppressing inflammatory signaling, GLP-1 decreases mitochondrial substrate
overload and indirectly limits oxidative stress at its source [3–7].
Overall, the interaction between GLP-1 signaling,
mitochondrial function, and oxidative stress regulation establishes GLP-1 as an
upstream metabolic regulator capable of integrating energy metabolism,
antioxidant defense, and cellular adaptation.
6. GLP-1 and Inflammatory Signaling Pathways
Chronic inflammation represents a major pathological
component of metabolic disorders and is closely interconnected with oxidative
stress. Persistent activation of inflammatory pathways promotes excessive
production of reactive oxygen species (ROS), disrupts redox homeostasis, and
accelerates progressive cellular and tissue injury [4–7].
A central regulator of inflammation-associated oxidative
damage is the nuclear factor-kappa B (NF-κB) signaling pathway, a
transcriptional system responsible for controlling the expression of numerous
pro-inflammatory genes, including cytokines, chemokines, adhesion molecules,
and stress-responsive mediators [4,7]. Under conditions of chronic metabolic
stress, sustained NF-κB activation contributes to metabolic inflammation,
endothelial dysfunction, impaired insulin signaling, and increased oxidative
burden, creating a self-amplifying cycle between inflammation and cellular
damage [4,7].
GLP-1 receptor signaling exerts important anti-inflammatory
effects by regulating inflammatory transcriptional networks and reducing
excessive NF-κB activation. Through suppression of NF-κB-dependent gene
expression, GLP-1 decreases production of inflammatory mediators and limits
chronic inflammatory responses associated with obesity, diabetes, and
cardiovascular disease [1–3,8].
In addition to inhibiting inflammatory pathways, GLP-1
enhances activation of the Nrf2 antioxidant pathway, thereby promoting
expression of cytoprotective genes involved in ROS detoxification and cellular
defense. This coordinated regulation of inflammatory and antioxidant mechanisms
establishes GLP-1 as a molecular link between immune modulation, oxidative
stress control, and metabolic adaptation [5,6].
The interaction between GLP-1 and inflammatory signaling is
particularly important in vascular tissues. Endothelial oxidative stress and
inflammation are major contributors to atherosclerosis, vascular dysfunction,
and cardiovascular complications associated with metabolic diseases. GLP-1
receptor agonists have demonstrated the ability to improve endothelial
function, increase nitric oxide bioavailability, reduce oxidative injury, and
suppress inflammatory activation within vascular cells [8,9,15].
Therefore, GLP-1-based therapies represent a broader
pharmacological approach that extends beyond glucose regulation by targeting
the interconnected pathways of metabolic inflammation, oxidative stress, and
cellular protection. Through simultaneous modulation of inflammatory signaling
and antioxidant defense, GLP-1 contributes to restoration of physiological
balance in metabolically stressed tissues [1–6].
7. Erythrocyte Oxidative Protection and Systemic Redox
Balance
Erythrocytes (red blood cells; RBCs) represent a unique
biological system continuously exposed to oxidative challenges because of their
essential role in oxygen transport and continuous interaction with hemoglobin
oxidation–reduction cycles. Despite their vulnerability to oxidative reactions,
mature erythrocytes lack both nuclei and mitochondria, making them entirely
dependent on cytoplasmic antioxidant mechanisms for maintaining structural
integrity and functional survival [4–7].
The primary protective mechanism in erythrocytes is the glutathione
(GSH)-dependent antioxidant system, which plays a fundamental role in
preserving membrane stability, regulating intracellular redox status, and
preventing excessive oxidation of hemoglobin to methemoglobin (metHb). Reduced
glutathione acts as a major antioxidant buffer, while enzymes such as glutathione
peroxidase (GPx) and glutathione reductase (GR) maintain continuous recycling
of oxidized and reduced glutathione pools [6–9].
Glutathione peroxidase contributes to erythrocyte
antioxidant protection by catalyzing the reduction of hydrogen peroxide (H₂O₂)
into water, thereby preventing accumulation of highly reactive oxidants. In
cooperation with additional antioxidant enzymes, including superoxide dismutase
and catalase, these systems protect erythrocyte membranes from lipid
peroxidation and preserve hemoglobin functionality during prolonged oxidative
exposure [6–9].
Although GLP-1 signaling has significant antioxidant and
anti-inflammatory effects in metabolic tissues, erythrocytes themselves are
unlikely to represent a direct cellular target of GLP-1 receptor activation
because mature RBCs lack nuclei, mitochondria, and receptor-mediated transcriptional
machinery. Instead, GLP-1 influences erythrocyte oxidative stability indirectly
through systemic metabolic regulation [1–6].
Improved glucose control, reduced metabolic inflammation,
decreased circulating reactive oxygen species (ROS), and enhanced systemic
antioxidant capacity may collectively reduce oxidative pressure on
erythrocytes. By lowering exposure to hyperglycemia-induced oxidative stress
and inflammatory mediators, GLP-1-based therapies may contribute to
preservation of erythrocyte membrane integrity, deformability, oxygen delivery
capacity, and cellular lifespan [1–6].
This systemic perspective highlights an important
distinction: GLP-1 does not directly modify erythrocyte antioxidant enzymes but
rather improves the extracellular metabolic environment that determines
erythrocyte oxidative burden. Therefore, erythrocyte protection represents an
indirect consequence of improved whole-body redox homeostasis and reduced
metabolic stress [2–6].
Overall, the relationship between GLP-1, erythrocyte
oxidative defense, and systemic antioxidant regulation demonstrates how
metabolic therapies can influence circulating blood components through upstream
modulation of inflammation and oxidative balance.
8. Clinical Implications and Therapeutic Perspectives
The expanding understanding of GLP-1 receptor signaling has
transformed the perception of GLP-1-based therapies from glucose-lowering
interventions into multifunctional treatments targeting interconnected pathways
of metabolism, inflammation, oxidative stress, and cellular protection.
Although originally developed for glycemic regulation in type 2 diabetes
mellitus, GLP-1 receptor agonists demonstrate broader biological effects
involving cardiovascular protection, metabolic improvement, and regulation of
systemic redox balance [1–3].
A major therapeutic implication of GLP-1 activity is its
ability to restore redox homeostasis in conditions characterized by excessive reactive
oxygen species (ROS) production. Chronic oxidative stress contributes to lipid
peroxidation, protein oxidation, mitochondrial dysfunction, and oxidative DNA
damage, which collectively accelerate tissue deterioration in metabolic and
degenerative diseases [4–7]. Through enhancement of endogenous antioxidant
pathways, including activation of the Nrf2–Keap1 pathway and improvement of the
glutathione (GSH) antioxidant system, GLP-1 signaling may reduce oxidative
injury and improve cellular resilience [5,6].
The cardiovascular benefits of GLP-1-based therapies are
closely associated with their effects on endothelial function and vascular
oxidative regulation. By reducing endothelial ROS generation, improving nitric
oxide bioavailability, and suppressing inflammatory activation, GLP-1 receptor
agonists contribute to improved vascular homeostasis and reduced cardiovascular
risk in metabolically compromised patients [8,9,15]. These mechanisms support
the concept that GLP-1 functions as a regulator of cardiometabolic protection
rather than merely a mediator of glucose control.
Beyond metabolic and cardiovascular disorders, modulation of
oxidative and inflammatory pathways suggests potential therapeutic relevance in
diseases where chronic redox imbalance contributes to progression. Conditions
including neurodegenerative disorders, chronic kidney disease, and inflammatory
diseases involve converging mechanisms of oxidative injury, mitochondrial
dysfunction, and immune activation [4,7,10]. Therefore, targeting GLP-1
signaling may provide a broader strategy for controlling disease-associated
oxidative damage.
The integration of metabolic signaling pathways with redox
biology represents an emerging framework in modern therapeutics. Unlike
conventional antioxidant approaches that directly neutralize free radicals,
GLP-1-based interventions regulate upstream biological mechanisms controlling
ROS generation, inflammation, mitochondrial efficiency, and endogenous
antioxidant capacity [1–6]. This multi-target regulatory effect highlights the
potential of GLP-1 receptor agonists as therapeutic agents for diseases characterized
by impaired metabolic adaptation and oxidative imbalance.
Future investigations should further clarify tissue-specific
GLP-1 mechanisms, identify biomarkers of antioxidant response, and determine
whether long-term modulation of GLP-1 signaling provides clinical benefits in
oxidative stress-associated disorders beyond established metabolic indications.
9. Conclusion
Glucagon-like peptide-1 (GLP-1) has emerged as a
multifunctional metabolic regulator that extends substantially beyond its
classical role in glucose-dependent insulin secretion. Increasing evidence
demonstrates that GLP-1 receptor signaling (GLP-1R) represents a central
molecular pathway connecting metabolic regulation, oxidative stress control,
inflammatory modulation, and cellular survival mechanisms.
Through activation of intracellular signaling networks,
including cAMP–PKA and EPAC pathways, GLP-1 enhances endogenous antioxidant
capacity by regulating key defense systems such as superoxide dismutase (SOD),
catalase, glutathione peroxidase (GPx), and the glutathione (GSH) system. These
responses strengthen cellular resistance against excessive reactive oxygen
species (ROS) accumulation and contribute to preservation of redox homeostasis.
GLP-1-mediated regulation of oxidative pathways also reduces
molecular damage involving lipid peroxidation, protein oxidation, and oxidative
DNA injury. In parallel, suppression of NF-κB-dependent inflammatory signaling
and activation of the Nrf2 antioxidant pathway establish GLP-1 as an important
molecular interface between inflammation and oxidative defense.
Although GLP-1 does not directly function as a mitochondrial
antioxidant or act directly on erythrocytes, its systemic effects indirectly
improve the stability of these systems by reducing glucotoxicity, lipotoxicity,
mitochondrial stress, and chronic inflammatory burden. This systemic mechanism
explains how GLP-1-based therapies can influence multiple organs and biological
compartments through coordinated regulation of metabolism and oxidative
balance.
Overall, GLP-1 receptor agonists represent promising
therapeutic strategies for diseases characterized by impaired redox regulation,
including metabolic disorders, cardiovascular disease, neurodegenerative
conditions, and chronic inflammatory states. The integration of GLP-1 biology
with oxidative stress research provides a foundation for future translational
approaches aimed at restoring metabolic flexibility, reducing cellular injury,
and promoting long-term tissue protection.
Mechanisms, Clinical Benefits, Safety Monitoring, and Nursing Considerations
Introduction
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs)
are a rapidly expanding class of incretin-based therapies originally developed
for the management of type 2 diabetes mellitus (T2DM). Their clinical
applications have expanded significantly due to their beneficial effects on weight
management, cardiovascular risk reduction, and metabolic disease
modification.¹
GLP-1 receptor agonists mimic the activity of
endogenous glucagon-like peptide-1 (GLP-1), an intestinal hormone
released after food intake. Physiologically, GLP-1 regulates glucose
metabolism, appetite, and gastrointestinal function by acting on multiple
organs, including the pancreas, gastrointestinal tract, brain, and
cardiovascular system.¹,²
For nurses, knowledge of GLP-1 receptor agonists is
increasingly important because nurses have a central role in:
• Patient education
• Medication administration and injection training
• Monitoring treatment response
• Recognizing adverse effects
• Supporting adherence
• Identifying complications requiring medical evaluation
1. Pharmacological Background and Mechanism of Action
1.1 The GLP-1 System
Endogenous GLP-1 is secreted primarily by intestinal
L-cells following nutrient ingestion. It acts as an incretin hormone by
enhancing insulin secretion in response to elevated blood glucose
levels.¹
However, natural GLP-1 has a very short biological
half-life because it is rapidly degraded by dipeptidyl peptidase-4 (DPP-4).
GLP-1 receptor agonists were developed as longer-acting molecules
capable of producing sustained metabolic effects.²
1.2 Pancreatic Effects
Enhancement of Insulin Secretion
GLP-1 receptor activation on pancreatic β-cells
increases insulin secretion.
A major pharmacological advantage is that this effect is glucose dependent.
Therefore:
• Insulin secretion increases mainly when glucose levels are elevated
• Risk of hypoglycemia is relatively low when GLP-1 RAs are used alone¹
However, hypoglycemia risk increases when combined
with:
• Insulin
• Sulfonylureas
Nursing considerations
Monitor for symptoms of hypoglycemia:
• Sweating
• Tremor
• Palpitations
• Confusion
• Dizziness
Suppression of Glucagon Secretion
GLP-1 receptor activation suppresses pancreatic
α-cell glucagon secretion during hyperglycemia.
GLP-1 receptor agonists represent integrated cardiometabolic therapies that improve glycemic control, reduce weight, and provide cardiovascular benefits. Nursing practice is central to safe and effective long-term use.
GLP-1 receptor agonists are incretin-based therapies initially developed for type 2 diabetes mellitus and now widely used in obesity and cardiometabolic risk management. They mimic endogenous glucagon-like peptide-1 (GLP-1), a gut-derived hormone involved in glucose regulation and appetite control.
1. Mechanism of Action
GLP-1 receptor agonists act through multiple physiological
pathways:
Enhance glucose-dependent insulin secretion from pancreatic β-cells
Act centrally on the hypothalamus to reduce appetite and increase satiety
These combined effects improve glycemic control while
reducing energy intake. ¹,¹³,¹⁴
2. Clinical Effects
Effects primarily mediated via appetite suppression and
reduced caloric intake¹
Glycemic control
Significant reduction in HbA1c across multiple trials
Low intrinsic risk of hypoglycemia when not combined with insulin or sulfonylureas
Weight reduction
Clinically meaningful weight loss in patients with obesity and type 2 diabetes
Cardiovascular outcomes
Large cardiovascular outcome trials (CVOTs) and
meta-analyses demonstrate:
Reduction in major adverse cardiovascular events (MACE) in high-risk populations
Decreased cardiovascular mortality in selected agents (e.g., liraglutide, semaglutide) ²,⁴,⁵,⁶,⁷
Renal and hepatic effects
Slower progression of albuminuria and eGFR decline in multiple analyses
Reduction in liver fat content and improvement in metabolic
dysfunction–associated steatotic liver disease signals ⁴,¹¹,¹²
3. Evidence Base (Key Trials)
Major cardiovascular outcome trials include:
LEADER (liraglutide) ⁵
SUSTAIN-6 (semaglutide) ⁶
REWIND (dulaglutide) ⁷
EXSCEL (exenatide) ⁸
Across these studies, GLP-1 receptor agonists consistently
demonstrated non-inferiority for cardiovascular safety, with several showing
superiority for MACE reduction. ³,⁵–⁸
Meta-analyses confirm a class-wide reduction in
cardiovascular events, particularly stroke and cardiovascular death in
high-risk patients. ⁴
4. Adverse Effects and Safety
Common adverse effects:
Nausea
Vomiting
Diarrhea or constipation
Early satiety and abdominal discomfort
Important risks
Gallbladder disease (increased risk in some populations)
Rare pancreatitis (causal association remains debated)
Transient worsening of diabetic retinopathy with rapid glycemic improvement in selected trials
Tolerability considerations
Gastrointestinal adverse effects remain the primary
limitation to adherence. Patient education and gradual titration are essential.
5. Contraindications and Precautions
Personal or family history of medullary thyroid carcinoma (based on preclinical rodent findings)
Multiple endocrine neoplasia type 2 (MEN2)
Caution in severe gastrointestinal motility disorders
Monitoring recommended in patients with advanced renal disease due to dehydration risk
6. Clinical Use Considerations
Often used in combination with metformin, SGLT2 inhibitors, or insulin.
Insulin or sulfonylurea doses may require reduction to prevent hypoglycemia
Long-term therapy is often required to maintain weight and metabolic benefits
Discontinuation is frequently associated with partial weight regain
7. Current Research Directions
Dual and triple incretin agonists (e.g., GLP-1/GIP
combinations)
Oral formulations with improved bioavailability
Expansion of cardiovascular and renal outcome indications
Investigation of neuropsychiatric, inflammatory, and
metabolic effects beyond diabetes ¹⁰,¹³,¹⁴
Summary
GLP-1 receptor agonists represent a class of multisystem
metabolic therapies that improve glycemic control, promote weight loss, and
reduce cardiovascular risk in selected populations. Their clinical utility
extends beyond glucose lowering into integrated cardiometabolic disease
modification. However, long-term adherence, gastrointestinal tolerability, and
cost remain key limitations.
این سایت برای آموزش بیوشیمی بالینی و تبادل آرا بین علاقمندان این علم طراحی شده است. نام سایت شامل دو کلمه است. دز مخفف دزفول بعنوان یکی از قدیمی ترین مراکز علم و تمدن در ایران و آز که مخفف آزمایشگاه است و اشاره به نقش تحقیقات در توسعه علم بیوشیمی دارد.
